VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Net of Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Net of Tax of -$66.51 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax for the quarter ending 2019-12-31 was -$20.82M, a 6014.77% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax for the quarter ending 2019-09-30 was $22.05M, a 348.86% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax for the quarter ending 2019-06-30 was -$9.20M, a 126.19% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax for the quarter ending 2019-03-31 was $5.34M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax for fiscal 2020 was -$66.51M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax for fiscal 2019 was -$2.63M, a 107.24% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax for fiscal 2018 was $36.35M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax for fiscal 2017 was -$32.74M, a 269.23% decline from fiscal 2016.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$66.51M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | -$20.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $1.23M derived: sum of 2 quarters · filed 2021-02-11 | -$7.97M derived: sum of 3 quarters · filed 2021-02-11 | -$2.63M 10-K · filed 2021-02-11 |
| 2019-09-30 | $22.05M 10-Q · filed 2019-10-31 | $12.85M derived: sum of 2 quarters · filed 2019-10-31 | $18.19M 10-Q · filed 2019-10-31 | $18.54M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | -$9.20M 10-Q · filed 2019-08-01 | -$3.86M 10-Q · filed 2019-08-01 | -$3.51M derived: sum of 3 quarters · filed 2021-02-11 | $1.40M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $5.34M 10-Q · filed 2019-05-01 | $5.69M derived: sum of 2 quarters · filed 2021-02-11 | $10.61M derived: sum of 3 quarters · filed 2021-02-11 | $45.74M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $5.26M derived: sum of 2 quarters · filed 2021-02-11 | $40.40M derived: sum of 3 quarters · filed 2021-02-11 | $36.35M 10-K · filed 2021-02-11 |
| 2018-09-30 | $4.91M 10-Q · filed 2019-10-31 | $40.05M derived: sum of 2 quarters · filed 2019-10-31 | $36.00M 10-Q · filed 2019-10-31 | $49.56M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $35.14M 10-Q · filed 2019-08-01 | $31.09M 10-Q · filed 2019-08-01 | $44.64M derived: sum of 3 quarters · filed 2020-02-13 | $41.27M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | -$4.05M 10-Q · filed 2019-05-01 | $9.51M derived: sum of 2 quarters · filed 2020-02-13 | $6.13M derived: sum of 3 quarters · filed 2020-02-13 | -$31.65M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $13.56M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $10.18M derived: sum of 2 quarters · filed 2020-02-13 | -$27.60M derived: sum of 3 quarters · filed 2020-02-13 | -$32.74M 10-K · filed 2020-02-13 |
| 2017-09-30 | -$3.38M 10-Q · filed 2018-10-25 | -$41.15M derived: sum of 2 quarters · filed 2018-10-25 | -$46.30M 10-Q · filed 2018-10-25 | -$21.28M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | -$37.78M 10-Q · filed 2018-07-26 | -$42.93M 10-Q · filed 2018-07-26 | -$17.91M derived: sum of 3 quarters · filed 2019-02-13 | -$18.36M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | -$5.15M 10-Q · filed 2018-04-27 | $19.87M derived: sum of 2 quarters · filed 2019-02-13 | $19.41M derived: sum of 3 quarters · filed 2019-02-13 | $20.92M derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $25.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $24.56M derived: sum of 2 quarters · filed 2019-02-13 | $26.07M derived: sum of 3 quarters · filed 2019-02-13 | $19.35M 10-K · filed 2019-02-13 |
| 2016-09-30 | -$455.00K 10-Q · filed 2017-10-30 | $1.05M derived: sum of 2 quarters · filed 2017-10-30 | -$5.67M 10-Q · filed 2017-10-30 | -$5.36M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $1.51M 10-Q · filed 2017-07-28 | -$5.21M 10-Q · filed 2017-07-28 | -$4.90M derived: sum of 3 quarters · filed 2018-02-15 | -$1.68M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$6.72M 10-Q · filed 2017-04-28 | -$6.41M derived: sum of 2 quarters · filed 2018-02-15 | -$3.19M derived: sum of 3 quarters · filed 2018-02-15 | -$5.69M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $313.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $3.53M derived: sum of 2 quarters · filed 2018-02-15 | $1.03M derived: sum of 3 quarters · filed 2018-02-15 | $907.00K 10-K · filed 2018-02-15 |
| 2015-09-30 | $3.22M 10-Q · filed 2016-10-31 | $720.00K derived: sum of 2 quarters · filed 2016-10-31 | $594.00K 10-Q · filed 2016-10-31 | $350.00K derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | -$2.50M 10-Q · filed 2016-08-01 | -$2.62M 10-Q · filed 2016-08-01 | -$2.87M derived: sum of 3 quarters · filed 2017-02-23 | -$1.68M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | -$126.00K 10-Q · filed 2016-05-03 | -$370.00K derived: sum of 2 quarters · filed 2017-02-23 | $814.00K derived: sum of 3 quarters · filed 2017-02-23 | $1.09M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | -$244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $940.00K derived: sum of 2 quarters · filed 2017-02-23 | $1.21M derived: sum of 3 quarters · filed 2017-02-23 | $1.22M 10-K · filed 2017-02-23 |
| 2014-09-30 | $1.18M 10-Q · filed 2015-10-30 | $1.46M derived: sum of 2 quarters · filed 2015-10-30 | $1.47M 10-Q · filed 2015-10-30 | $1.71M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | $274.00K 10-Q · filed 2015-08-04 | $283.00K 10-Q · filed 2015-08-04 | $527.00K derived: sum of 3 quarters · filed 2016-02-16 | $1.21M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | $9.00K 10-Q · filed 2015-05-04 | $253.00K derived: sum of 2 quarters · filed 2016-02-16 | $933.00K derived: sum of 3 quarters · filed 2016-02-16 | $852.00K derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $924.00K derived: sum of 2 quarters · filed 2016-02-16 | $843.00K derived: sum of 3 quarters · filed 2016-02-16 | $244.00K 10-K · filed 2016-02-16 |
| 2013-09-30 | $680.00K 10-Q · filed 2014-11-06 | $599.00K derived: sum of 2 quarters · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | -$134.00K derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$81.00K 10-Q · filed 2014-07-31 | -$680.00K 10-Q · filed 2014-07-31 | -$814.00K derived: sum of 3 quarters · filed 2015-02-13 | -$557.00K derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | -$599.00K 10-Q · filed 2014-05-05 | -$733.00K derived: sum of 2 quarters · filed 2015-02-13 | -$476.00K derived: sum of 3 quarters · filed 2015-02-13 | -$521.00K derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | -$134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $123.00K derived: sum of 2 quarters · filed 2015-02-13 | $78.00K derived: sum of 3 quarters · filed 2015-02-13 | $503.00K 10-K · filed 2015-02-13 |
| 2012-09-30 | $257.00K 10-Q · filed 2013-11-07 | $212.00K derived: sum of 2 quarters · filed 2013-11-07 | $637.00K 10-Q · filed 2013-11-07 | |
| 2012-06-30 | -$45.00K 10-Q · filed 2013-08-02 | $380.00K 10-Q · filed 2013-08-02 | ||
| 2012-03-31 | $425.00K 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | $14.00K 10-K · filed 2014-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |